Tuesday, 9 August 2022
  
Login

Australia's most trusted
source of pharma news

Tuesday, 09 August 2022
Listen to this story 
News

New CSL venture ready for take off

Posted 2 August 2022 PM

CSL has finally completed its mammoth Vifor acquisition, after two delays due to regulatory speed bumps.

In December last year CSL announced the AU$17.2 billion buy of the Swiss pharma to get a solid position in the renal market. Expected to be closed by March, the settlement was postponed for four months until 22 July. Then on 13 July it was again postponed, to 30 September, waiting on regulatory clearances.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (11)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.